|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 413.70 SEK | +0.41% |
|
+2.79% | +24.16% |
| 12:16am | Pareto Securities raises Sobi target price to SEK 460 (430), reiterates Buy | FW |
| Apr. 15 | Berenberg Expects Double-Digit Q1 Revenue Growth for Sobi; Buy Rating Maintained | MT |
Business description: Swedish Orphan Biovitrum AB
Number of employees: 1,862
Sales by Activity: Swedish Orphan Biovitrum AB
| Fiscal Period: December | 2021 (SEK) | 2022 (SEK) | 2023 (SEK) | 2024 (SEK) | 2025 (SEK) |
|---|---|---|---|---|---|
Haematology | 8.54B | 10.83B | 13.37B | 16.43B | 19.12B |
Immunology | 5.78B | 6.68B | 7.64B | 8.33B | 7.81B |
Specialty Care | 1.21B | 1.28B | 1.12B | 1.27B | 1.31B |
Geographical breakdown of sales: Swedish Orphan Biovitrum AB
| Fiscal Period: December | 2021 (SEK) | 2022 (SEK) | 2023 (SEK) | 2024 (SEK) | 2025 (SEK) |
|---|---|---|---|---|---|
United States | 6.05B | 7.36B | 8.15B | 8.37B | 9.14B |
Europe (Excluding Sweden & Germany) | - | - | - | - | 7.51B |
Other | 1.25B | 1.43B | 2.72B | 4.9B | 4.29B |
International | 1.15B | 2.44B | 2.65B | 2.92B | 3.82B |
Germany | 1.23B | 1.6B | - | - | 3.01B |
Sweden | 678M | 667M | 660M | 653M | 293M |
North America (Excluding United States) | 66M | 77M | 93M | 142M | 176M |
Rest of Europe | 3.3B | 3.58B | - | - | - |
France | 1.8B | 1.63B | - | - | - |
Europe (Excluding Sweden) | - | - | 7.85B | 9.04B | - |
Executive Committee: Swedish Orphan Biovitrum AB
| Manager | Title | Age | Since |
|---|---|---|---|
Guido Oelkers
CEO | Chief Executive Officer | 61 | 2017-05-21 |
Henrik Stenqvist
DFI | Director of Finance/CFO | 59 | 2018-07-19 |
| Chief Tech/Sci/R&D Officer | 55 | - | |
| Chief Tech/Sci/R&D Officer | 51 | 2009-12-31 | |
Lena Bjurner
HRO | Human Resources Officer | 58 | 2022-12-31 |
Composition of the Board of Directors: Swedish Orphan Biovitrum AB
| Director | Title | Age | Since |
|---|---|---|---|
Staffan Schüberg
BRD | Director/Board Member | 57 | 2019-12-31 |
| Director/Board Member | 70 | 2020-12-31 | |
Filippa Stenberg
BRD | Director/Board Member | - | - |
| Director/Board Member | 56 | 2022-12-31 | |
Mats Lek
BRD | Director/Board Member | 43 | 2022-12-31 |
Katy Mazibuko
BRD | Director/Board Member | 53 | 2022-12-31 |
Zlatko Rihter
BRD | Director/Board Member | 56 | 2024-05-13 |
David Meek
CHM | Chairman | 61 | 2024-12-10 |
| Director/Board Member | 65 | 2025-05-07 |
Holdings: Swedish Orphan Biovitrum AB
| Name | Equities | % | Valuation |
|---|---|---|---|
| 12,557,222 | 3.51% | 517 M $ |
Company details: Swedish Orphan Biovitrum AB
Biopharmaceuticals
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.41% | +2.79% | +57.47% | +52.36% | 15.55B | |
| -0.68% | -2.29% | +36.59% | -8.48% | 77.37B | |
| -3.80% | -6.03% | +84.54% | +190.89% | 59.71B | |
| +4.30% | +60.20% | +60.20% | +60.20% | 50.37B | |
| -1.36% | -1.91% | -43.14% | -54.43% | 47.92B | |
| -2.08% | +0.21% | +53.94% | -39.26% | 26.5B | |
| -2.26% | +3.87% | +111.45% | -63.00% | 21.52B | |
| -1.20% | -1.43% | +65.55% | +27.43% | 19.32B | |
| -0.95% | +1.28% | +125.97% | +408.92% | 15.06B | |
| +5.67% | -0.40% | -1.84% | +609.13% | 13.56B | |
| Average | -0.17% | +1.31% | +55.07% | +118.37% | 34.69B | |
| Weighted average by Cap. | -0.52% | +0.12% | +48.16% | +70.72% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- SOBI Stock
- Company Swedish Orphan Biovitrum AB
Select your edition
All financial news and data tailored to specific country editions
